Celgene Corporation today announced that it has completed its purchase of the research and office facility located at 556 Morris Avenue in Summit. The purchase of the 556 Morris Avenue campus extends the company’s existing Summit presence beyond its 86 Morris Avenue global headquarters location.
The acquisition of the 556 Morris Avenue facility along with the completion of construction of a new 550,000 square foot office building at its 86 Morris Avenue location allows Celgene to concentrate its New Jersey operations at two campuses in close proximity in Summit.
“This acquisition marks an important milestone in our company’s growth in New Jersey and our long relationship as a proud resident of Summit,” said Bob Hugin, Chairman and CEO of Celgene. “A vibrant biopharmaceutical sector benefits patients, the healthcare system, and our local communities. With this new site and the soon to be completed new building at our headquarters location, we are building an even stronger presence in this great community.”
The 556 Morris Avenue site includes research and development facilities, laboratory and support buildings, manufacturing capabilities, storage, warehouse buildings, and administrative office space. The site has approximately 850,000 square feet of administrative office space and 450,000 square feet of R&D space.Related Articles: